Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.59 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254938 | 0.94 | SRC (0.90) | SRCALDH1A1LMNARAB9ATRPV1 | |
| SCHEMBL28229572 | 0.94 | SRC (0.90) | SRCALDH1A1LMNARAB9ATRPV1 | |
| SCHEMBL538601 | 0.93 | SRC (0.87) | SRCALDH1A1LMNARAB9ATRPV1 | |
| SCHEMBL10168874 | 0.92 | SRC (0.85) | SRCALDH1A1LMNARAB9ATRPV1 | |
| SCHEMBL16572072 | 0.89 | SRC (0.79) | SRCALDH1A1LMNARAB9ATRPV1 | |
| SCHEMBL254591 | 0.88 | SRC (0.79) | SRCALDH1A1LMNARAB9AMAPK1 | |
| SCHEMBL254158 | 0.87 | SRC (0.77) | SRCALDH1A1LMNARAB9ATRPV1 | |
| SCHEMBL11917367 | 0.87 | SRC (0.77) | SRCALDH1A1LMNARAB9ATRPV1 | |
| SCHEMBL254477 | 0.86 | SRC (0.76) | SRCALDH1A1LMNARAB9AERCC1 | |
| SCHEMBL15912208 | 0.86 | SRC (0.75) | SRCALDH1A1LMNARAB9ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | ATHENEX, INC. | 2024-02-15 | — | — | US | disclosed |
| US-11325885-B2 | Method for treating stomach cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2022-05-10 | — | — | US | disclosed |
| US-11312680-B2 | Method for treating a patient having a colon cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2022-04-26 | — | — | US | disclosed |
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-04-21 | — | — | US | disclosed |
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-04-21 | — | — | US | disclosed |
| US-11214537-B2 | Method for making anti-cancer compounds | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-04 | — | — | US | disclosed |
| US-20210395187-A1 | METHOD FOR TREATING A PATIENT HAVING A COLON CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-23 | — | — | US | disclosed |
| US-20210380526-A1 | METHOD FOR TREATING STOMACH CANCER | KING ABDULAZIZ UNIVERSITY (SA) | 2021-12-09 | — | — | US | disclosed |
| US-20210340097-A1 | METHOD FOR MAKING ANTI-CANCER COMPOUNDS | KING ABDULAZIZ UNIVERSITY (SA) | 2021-11-04 | — | — | US | disclosed |
| US-11142493-B1 | Pharmaceutical composition for treating cancer | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-12 | — | — | US | disclosed |
| US-7300931-B2 | Compositions for treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300931-B2 | Compositions for treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300931-B2 | Compositions for treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20060160800-A1 | Morpholino-2-[6-(2-Ethoxy-phenyl)-pyridin-3-yl]-benzyl)-acetamide compound; as anti-proliferative agents, for treating mammals | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380526-A1 | METHOD FOR TREATING STOMACH CANCER | TUBB, TUBB1, TUBA1C | SRC 5/4885ALDH1A1 3409/4885LMNA 2474/4885 |
| US-20210395187-A1 | METHOD FOR TREATING A PATIENT HAVING A COLON CANCER | TUBB1, TUBA1C, TUBB | SRC 7/4885ALDH1A1 2594/4885LMNA 2017/4885 |
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K6, MAP3K8 | SRC 116/4885ALDH1A1 4221/4885LMNA 2551/4885 |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885ALDH1A1 4492/4885LMNA 1904/4885 |
| US-20060160800-A1 | Morpholino-2-[6-(2-Ethoxy-phenyl)-pyridin-3-yl]-benzyl)-acetamide compound; as anti-proliferative agents, for treating mammals | MKI67, PCNA, CCAR2 | SRC 3344/4885ALDH1A1 1111/4885LMNA 1629/4885 |
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | SRC 76/4885ALDH1A1 4492/4885LMNA 1904/4885 |
| US-11214537-B2 | Method for making anti-cancer compounds | MCL1, TUBB, TUBB1 | SRC 7/4885ALDH1A1 3075/4885LMNA 1640/4885 |
| US-20210340097-A1 | METHOD FOR MAKING ANTI-CANCER COMPOUNDS | MCL1, TUBB, TUBB1 | SRC 7/4885ALDH1A1 3075/4885LMNA 1640/4885 |
| US-11312680-B2 | Method for treating a patient having a colon cancer | TUBB1, TUBA1C, TUBB | SRC 7/4885ALDH1A1 2594/4885LMNA 2017/4885 |
| US-11325885-B2 | Method for treating stomach cancer | TUBB, TUBB1, TUBA1C | SRC 5/4885ALDH1A1 3409/4885LMNA 2474/4885 |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | MKI67, CCNC, CCNA1 | SRC 430/4885ALDH1A1 2075/4885LMNA 341/4885 |
| US-11142493-B1 | Pharmaceutical composition for treating cancer | SRC, TUBA1C, TUBB | SRC 1/4885ALDH1A1 3706/4885LMNA 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.